

**NOTICE**

NOTICE is hereby given that the Seventh (7<sup>th</sup>) Annual General Meeting of the Members of Assam Cancer Care Foundation will be held, at shorter notice, at the Board Room, Business Centre of Vivanta by Taj, Guwahati on Monday, the 30<sup>th</sup> day of September 2024 at 03:30 pm. to transact the following business:

**ORDINARY BUSINESS:**

1. To consider, approve and adopt the Audited Financial Statements of the Company comprising the Statements of Income and Expenditure and Cash Flow for the financial year ended on March 31, 2024, and the Balance Sheet as that date, together with the Reports of the Board of Directors and Auditors thereon.

**By the order of the Board  
For Assam Cancer Care Foundation**



**Dr Siddharth Singh  
(Director)**

**DIN: 08251430**

**Date: 30th September 2024  
Place : Guwahati**

**NOTES:**

1. A member entitled to attend and vote at the Annual General Meeting (the "Meeting") is entitled to appoint a proxy to attend and vote on a poll instead of himself/herself and the proxy shall be a member of the Company.
2. The documents referred to in the Notice and Explanatory Statement, will be available for inspection by the members at the Registered office of the Company during business hours between 09:30 A.M. to 05:30 P.M. (except Saturday and Sunday) up to the date of the Annual General Meeting and will also be available during the Annual General Meeting.

**By order of the Board,  
For Assam Cancer Care Foundation**



**Dr Siddharth Singh**  
(Director)  
**DIN: 08251430**

**Date: 30th September 2024**  
**Place : Guwahati**

## DIRECTORS' REPORT

To,  
The Members,  
ASSAM CANCER CARE FOUNDATION

The Directors are pleased to present the 7th Annual Report of Assam Cancer Care Foundation on the operations of the Company for the financial year ended on 31st March 2024 together with the Audited Financial Statements along with the Report of the Auditors thereon.

### 1. OPERATIONAL HIGHLIGHTS:

Assam Cancer Care Foundation ("ACCF" or "the Company") was incorporated as a not-for-profit company under Section 8 of the Companies Act, 2013 in December 2017 to set up a network of cancer care hospitals in the State of Assam. In the 1<sup>st</sup> Phase, the Company was to set up ten cancer care hospitals and in the 2<sup>nd</sup> Phase, seven more hospitals were to be set up.

On 28<sup>th</sup> April 2022, Shri Narendra Modi, Hon'ble Prime Minister of India, in the presence of Dr. Himanta Biswa Sarma, Hon'ble Chief Minister of Assam, Shri Ratan Tata, Chairman, Tata Trusts and a host of other dignitaries, dedicated to the nation, seven cancer care hospitals of ACCF located at Dibrugarh, Barpeta, Tezpur, Lakhimpur, Jorhat, Kokrajhar and Darrang. On 1<sup>st</sup> March 2024, Silchar Cancer Centre and on 2<sup>nd</sup> March 2024, State Cancer Institute (SCI) Guwahati were inaugurated by Hon'ble Chief Minister of Assam, Dr. Himanta Biswa Sarma. The hospital in Diphu is likely to start operations by March 2025. The construction of the remaining hospitals in Phase 2 viz. Sivasagar, Tinsukia, Dhubri, Golaghat, Nalbari, Nagaon and Goalpara, are at various stages of construction and are likely to be completed over 2026 and 2027.

The L2 hospitals (Dibrugarh, Barpeta and Silchar) provide Medical Oncology - chemotherapy, Surgical Oncology, Radiation Oncology, Palliative Care services, Critical Care, Blood Centre, Diagnostic facilities including MRI, PET-CT, CT scan, Digital X-Ray, Mammography, high-end USG and Advanced Laboratories. Dibrugarh Cancer Centre has also received NABH accreditation effective from 27<sup>th</sup> June 2023.

The L3 hospitals (Tezpur, Jorhat, Lakhimpur, Kokrajhar and Darrang) provide Medical Oncology - chemotherapy, Radiation Oncology, Palliative Care services, Diagnostic facilities including MRI, CT scan, Digital X-Ray, Mammography, high- end USG in radiology and basic Laboratories.

ACCF hospitals are empaneled under AAA/PMJAY/CMJAY schemes for cashless treatment of the patients. In addition, ACCF hospitals are empaneled with ECHS, CGHS, 6 PSUs (NF Railways, NRL, BCPL, APPL, OIL, CIL) and 14 TPA/Insurance providers. Three hospitals at Barpeta, Dibrugarh, Tezpur, and Day Care Centre at Diphu are also empaneled under ESIC.

ACCF is actively collaborating with the National Health Mission to enhance cancer screening and early detection. ACCF's Community Outreach Program (COP) is presently operational in ten districts of Barpeta, Cachar, Darrang, Jorhat, Dibrugarh, Karbi Anglong, Kokrajhar, Lakhimpur, Charaideo and Dhemaji. These programs are supported through CSR funds provided by various donors. The program is being extended to another 5 districts - Bongaigaon, Baksa, Udalguri,

Sivasagar and Hailakandi with support from a new CSR donor. Continuous efforts are being made to raise CSR funds for all other districts.

Besides the awareness and screening programs, the COP team also acts as a bridge between ACCF hospitals and communities for all ancillary services. Many patients discharged from hospitals need regular support especially for palliative care. It is very difficult and inconvenient for these patients to visit the hospitals to avail palliative care. Therefore, home-based palliative care has been introduced under ACCF's Community Outreach Program which is running in collaboration with National Program for Palliative Care. Home-based palliative care provides a lot of relief to such patients as it eliminates travel and financial burden. This also gives a boost to the cancer care program and support in the continuum of care for cancer patients, where each patient is tracked and served end to end.

In addition, ACCF is operating four kiosks located in Medical Colleges at Silchar, Barpeta, Dibrugarh, and Diphu. These kiosks are located at accessible locations where individuals can undergo screenings for oral, breast, and cervical cancers.

The patient services data for the period April 2023 till March 2024 is given in the table below:

PATIENT SERVICE & STATISTICS (Apr 2023 - Mar 2024)												
Hospital	OPD Patients	New Registrations	IPD Bed days	Major OT	Chemo (Daycare)	Radiation	Lab Tests	CT	MRI	XRAY	USG	PET CT
DIBRUGARH	26220	8398	15620	379	3457	15559	78473	3803	2815	1730	628	608
BARPETA	16190	7556	9771	201	4420	12041	36420	6773	1611	1062	300	-
JORHAT	12445	6931	-	-	3702	10307	19605	5858	2134	660	0	-
TEZPUR	10251	2833	-	-	3802	6534	14639	1543	605	256	289	-
LAKHIMPUR	6195	3847	-	-	996	3811	7127	1236	2557	265	257	-
KOKRAJHAR	6917	4769	-	-	1121	2624	9845	977	1314	4419	84	-
DARRANG	10774	5128	-	-	1444	5791	10971	1304	1881	577	1652	-
SILCHAR	121	78	-	-	8	0	10	0	0	0	0	-
TOTAL	89113	39540	25391	580	18950	56667	177090	21494	12917	8969	3210	608

## 2. FINANCIAL RESULTS:

(Rs. Lakh)

Particulars	2023 - 24	2022 - 23
Grant Income	15364.82	16,307.40
Other Income	72.14	58.24
Income from treatment of patient	8802.86	4,025.02
Total Income	24,239.83	20,390.66
Total Expenditure	24,167.68	20,332.43
Excess of Income over Expenditure	72.14	58.23

## 3. CHANGE IN NATURE OF BUSINESS:

There is no change in the nature of business of ACCF during the financial year under report.

## 4. MEETINGS OF THE BOARD: -

Two Board Meetings were held during the financial year under report:

Sr. No.	Dates on which the Board Meetings were held	Total strength of the Board	No. of Directors Present
1	26 <sup>th</sup> July 2023	6	6
2	30 <sup>th</sup> September 2023	6	5

**Attendance of Directors at Board Meetings and Annual General Meeting: -**

Names of the Directors	Attendance at the Board Meeting held on		Annual General Meeting 30-Sept-2023
	26 <sup>th</sup> July 2023	30 <sup>th</sup> September 2023	
Dr. Himanta Biswa Sarma	Present	Present	Present
Mr. Keshab Mahanta	Present	Present	Present
Mr Vijay Singh	Present	Absent	Absent
Dr Siddharth Singh	Present	Present	Present
Mr Siddharth Sharma	Present	Present	Present
Dr Pattatheyil Arun	Present	Present	Present

**5. DIRECTORS AND KEY MANAGERIAL PERSONNEL (KMP): -**

Dr Pattatheyil Arun, Director, TMCH and Mr Siddharth Sharma, CEO, Tata Trusts, who were earlier appointed by the Board as Additional Directors, were appointed as Directors by the members at the Annual General Meeting held on 30/09/2023. Ms. Nelbymol Nelson ceased to be the Company Secretary with effect from 15<sup>th</sup> September 2023.

The details of the Directors and Key Managerial Personnel of the Company as on 31/03/2024 are as follows:

SL No.	Name of Directors/KMP	Designation	Date of appointment
1.	Dr Himanta Biswa Sarma, Hon'ble Chief Minister, Assam	Chairman & Nominee Director	05/05/2018
2.	Sri Keshab Mahanta, Hon'ble Health Minister, Assam	Nominee Director	30/11/2021
3.	Sri Vijay Singh, Vice Chairman, Tata Trusts	Director	08/05/2019
4.	Dr Siddharth Singh, IAS, Commissioner and Secretary, Medical Education and Research Department, Govt of Assam	Nominee Director	16/06/2022
5.	Mr Siddharth Sharma, CEO, Tata Trusts	Director	08/03/2023
6.	Dr Pattatheyil Arun, Director, TMC, Kolkata	Director	07/02/2023

**6. DETAILS OF FRAUD REPORTED BY AUDITOR: -**

Pursuant to section 143(12) of the Act, the statutory auditors of the Company have not reported any fraud on the Company by its officers or employees, the details of which are required to be mentioned in the Board's Report.

**7. AUDITORS:-**

M/s. Deloitte Haskins & Sells LLP Chartered Accountants (Firm Registration No. 117366W/W-1000018), were appointed as the Statutory Auditors of the Company for a period of 5 years at the 6th Annual General Meeting (AGM) of the Company held on 30<sup>th</sup> September 2023 to hold office up to the conclusion of the AGM to be held in the year 2028. They have confirmed their eligibility to continue as Statutory Auditors of the Company.

**8. AUDITORS' REPORT:**

The Auditors' Report for the financial year 2023-2024 does not contain any qualification, reservation, or adverse remarks. Notes to Accounts and Auditors' remarks in their report are self-explanatory and do not require any further comments.

**9. CONTRACT AND ARRANGEMENTS WITH RELATED PARTIES: -**

There were no related party transactions entered into during the year ended on 31st March, 2024.

**10. DEPOSITS:**

During the year under review, the Company neither accepted nor renewed any deposits falling within the ambit of Section 73 of the Companies Act, 2013 and the Companies (Acceptance of Deposits) Rules, 2014.

**11. PARTICULARS OF INVESTMENTS, LOANS, GUARANTEES UNDER SECTION 186 OF THE COMPANIES ACT, 2013:**

During the year under review, the Company did not give any loans, guarantees or make any investment covered under the provisions of Section 186 of the Companies Act, 2013.

**12. TRANSFER TO RESERVES:**

No amount was transferred to Reserves during the year ended on 31<sup>st</sup> March 2024.

**13. MATERIAL CHANGES AND COMMITMENTS, AFFECTING THE FINANCIAL POSITION OF THE COMPANY WHICH HAVE OCCURRED BETWEEN THE END OF THE FINANCIAL YEAR OF THE COMPANY TO WHICH THE FINANCIAL STATEMENTS RELATE AND THE DATE OF THE REPORT:**

No material changes and commitments affecting the financial position of the Company have occurred between the end of the financial year and the date of this report.

**14. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO: -**

The details pursuant to Rule 8 of the Companies (Accounts) Rules, 2014 concerning conservation of energy, technology absorption and foreign exchange earnings and outgo is attached hereto as **Annexure I**.

**15. STATEMENT CONCERNING DEVELOPMENT AND IMPLEMENTATION OF RISK MANAGEMENT POLICY OF THE COMPANY: -**

The management has drawn up a Risk Management Policy which has been approved by the Board and adopted.

**16. ANNUAL RETURN**

Pursuant to Section 92(3) of the Companies Act, 2013, the Annual Return for the financial year 2023-2024 is available on the website of the Company at [www.assamcancercarefoundation.org](http://www.assamcancercarefoundation.org)

**17. CORPORATE SOCIAL RESPONSIBILITY (CSR):-**

The provisions of Section 135(1) of the Companies Act, 2013 are not applicable to the Company for the year under review.

**18. SUBSIDIARY AND ASSOCIATE COMPANIES: -**

The Company does not have any Subsidiary/Associate/JV Company.

**19. DETAILS OF SIGNIFICANT MATERIAL ORDERS PASSED BY THE REGULATORS / COURTS / TRIBUNAL IMPACTING THE GOING CONCERN STATUS AND COMPANY'S OPERATIONS IN FUTURE: -**

There are no significant material or other orders passed by the Regulators / Courts / Tribunal which would impact the going concern status of the Company and its future operations. Hence, there is no disclosure to be made pursuant to Rule 8 (5) (vii) of Companies (Accounts) Rules, 2014.

**20. SEXUAL HARRASSMENT OF WOMEN AT THE WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013: -**

A policy on Prevention, Prohibition and Redressal of Sexual Harassment has been adopted by the Company and notified to the employees. The Company has constituted an Internal Committee ("IC") as required under the Act for the head office and all functional units as well.

No complaints have been filed with the Internal Committee during the year under report. Two workshops on creating awareness on Prevention of Sexual Harassment were conducted for employees and IC members.

**21. DETAILS IN RESPECT OF ADEQUACY OF INTERNAL FINANCIAL CONTROLS WITH REFERENCE TO THE FINANCIAL STATEMENTS PURSUANT TO RULE 8 (5) (VIII) OF COMPANIES (ACCOUNTS) RULES, 2014:**

The Company has adequate internal financial controls with reference to the financial statements, commensurate with the size and nature of its operations.

**22. DISCLOSURE OF MAINTANENCE OF COST RECORDS AS SPECIFIED BY THE CENTRAL GOVERNMENT UNDER SUB-SECTION (1) OF SECTION 148 OF THE COMPANIES ACT, 2013:**

The provisions of Section 148 of the Companies Act, 2013 pertaining to maintenance of Cost Records are not applicable to the Company.

**23. APPLICATION MADE OR PROCEEDINGS PENDING UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016:**

During the year under review, no application was made under the Insolvency and Bankruptcy Code, 2016 ("IBC 2016") by the Company. No proceedings are pending under IBC 2016 against the Company.

**24. PARTICULARS OF VALUATION DONE AT THE TIME OF ONE-TIME SETTLEMENT AND VALUATION DONE WHILE TAKING LOAN FROM THE BANKS OR FINANCIAL INSTITUTIONS:**

During the year under review, there were no instances of any one-time settlement of loans taken from Banks or Financial Institutions.

**25. DIRECTORS' RESPONSIBILITY STATEMENT: -**

Pursuant to the requirement under Section 134 (3) (c) of the Companies Act, 2013 (the "Act") with respect to Directors' Responsibility Statement, it is hereby confirmed that:


- (a) in the preparation of the annual accounts for the financial year ended on 31<sup>st</sup> March, 2024, the applicable accounting standards have been followed along with proper explanation relating to material departures;
- (b) the Directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as at 31<sup>st</sup> March, 2024 and of the excess of income over expenditure of the Company for the year ended on that date;
- (c) the Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act, for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- (d) the Directors have prepared the annual accounts on a going concern basis; and
- (e) the Directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems are adequate and operating effectively.

**26. ACKNOWLEDGMENT:**

The Board wishes to place on record its appreciation and gratitude for the support and assistance received from the Government of Assam and all those with whom the Company has had dealings and the employees.

For and on behalf of the Board

  
Siddharth Singh  
(Director)  
DIN: 08251430

  
Pattatheyil Arun  
(Director)  
DIN: 10043845

Place: Guwahati  
Date: 30<sup>th</sup> September 2024

## **Annexure I to the Directors' Report**

Information pursuant to Section 134 of the Companies Act, 2013 read with Rule 8 of the Companies (Accounts) Rules, 2014 and forming part of the Directors' Report for the year ended on 31<sup>st</sup> March, 2024.

### **A. CONSERVATION OF ENERGY:**

#### **i. Energy Conservation measures taken:**

ACCF is taking proactive steps for saving energy. While adopting the design for electrical systems for the upcoming hospitals, ACCF has selected variable frequency drives for all services like HVAC, water, fire and chiller pumps etc. These systems have distinct advantages of saving of energy by upto 67% reinforcing ACCF's commitment towards clean environment by reduction of CO<sub>2</sub>.

Further, LED lights are being used in all the hospitals, which results in saving of around 50% in lighting loads. The project is also using the Hybrid power factor control panels to control reactive power as well as Total Harmonic Distortion (THD).

#### **ii. Capital investments, if any; on energy conservation equipment**

As the work is being executed through a design and build contract, no additional investment is required for implementing the conservation measures as these were included in the Design Basis Report (DBR) of the projects.

#### **iii. Alternate sources of energy, if any utilized by the Company**

The hospitals have provision for usage of solar power for 50% hot water requirements.

#### **iv. Impact of measures at (i), (ii) & (iii) above for reduction of energy consumption and consequent impact on cost of production of goods:**

It is expected that the measures taken will provide reduction in the annual energy consumption and cost.

### **B. TECHNOLOGY ABSORPTION**

#### **i. Efforts made in technology absorption:**

Assam falls under Seismic Zone V, which is the most seismic active zone. ACCF has been in the forefront of adopting new technology for the projects it has undertaken. For all the hospital buildings, it has gone for adoption of National Disaster Management Authority (NDMA) guidelines compliant building using Base Isolation technology. Under this, the buildings are designed to take double of the horizontal force compared to conventional earthquake resistant structures (as per IS 4326, 1993). The adoption has the following identified benefits:

- a) The beam-column structural frame sizing has come down providing better coordination of services in the hospital buildings
- b) The buildings are highly resistant to collapse in case of any disaster that could lead to any loss of life. The hospitals can continue to function and provide services, while the building can serve as a critical community facility when it is most needed;
- c) It is designed, with contingency plans in place and health workforce will be trained to keep the network operational

#### **C. FOREIGN EXCHANGE EARNINGS AND OUTGO**

- i. Activities relating to Export; initiatives taken to increase exports; development of new export markets for products and export plans:**

The Company is not engaged in any export activities.

- ii. Total foreign exchange used and earned:**

- **Foreign Exchange Earned – NIL**
- **Foreign Exchange Spent – NIL**

## **INDEPENDENT AUDITOR'S REPORT**

**To,**  
**The Members of Assam Cancer Care Foundation**  
**Report on the Audit of the Financial Statements**

### **Opinion**

We have audited the accompanying financial statements of Assam Cancer Care Foundation ("the Company"), which comprise the Balance Sheet as at 31<sup>st</sup> March 2024, and the Statement of Income and Expenditure, the Cash Flow Statement for the year ended on that date, and notes to the financial statements, including a summary of material accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the Accounting Standards prescribed under section 133 of the Act read with the Companies (Accounting Standards) Rules, 2006, as amended ("Accounting Standards") and other accounting principles generally accepted in India, of the state of affairs of the Company as at 31<sup>st</sup> March 2024, and its excess of income over expenditure and its cash flows for the year ended on that date.

### **Basis for Opinion**

We conducted our audit of the financial statements in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibility for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

### **Information Other than the Financial Statements and Auditor's Report Thereon**

- The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Director's report but does not include the financial statements and our auditor's report thereon.
- Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

## **Deloitte Haskins & Sells LLP**

- In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements, or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.
- If based on the work we have performed on the other information that we obtained prior to the date of this auditor's report, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

### **Responsibilities of Management and Those Charged with Governance for the Financial Statements**

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including Accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management and Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Company's Board of Directors are also responsible for overseeing the Company's financial reporting process.

### **Auditor's Responsibility for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

J

## **Deloitte Haskins & Sells LLP**

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances but not for the purpose of expressing an opinion on the effectiveness of company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal financial controls that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

### **Report on Other Legal and Regulatory Requirements**

1. As required by Section 143(3) of the Act, based on our audit we report that:
  - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.

- b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
- c) The Balance Sheet, the Statement of Income and Expenditure and the Cash Flow Statement dealt with by this Report are in agreement with the relevant books of account.
- d) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act.
- e) On the basis of the written representations received from the directors as on 31<sup>st</sup> March, 2024 taken on record by the Board of Directors, none of the directors is disqualified as on 31<sup>st</sup> March, 2024 from being appointed as a director in terms of Section 164(2) of the Act.
- f) Reporting on the adequacy of Internal Financial Controls with reference to financial statements of the Company and the operating effectiveness of such controls, under section 143(3)(i) of the Act is not applicable in view of the exemption available to the Company in terms of the notification no. G.S.R. 583(E) dated 13 June 2017 issued by the Ministry of Corporate Affairs, Government of India, read with general circular No. 08/2017 dated 25 July 2017.
- g) In our opinion and to the best of our information and according to the explanations given to us, the Company being a private company, section 197 of the Act related to the managerial remuneration is not applicable.
- h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended in our opinion and to the best of our information and according to the explanations given to us:
  - i. The Company has disclosed the impact of pending litigations on its financial position in its financial statements.
  - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
  - iii. There were no amount which were required to be transferred to Investor Education and Protection fund by the company.
  - iv.
    - (a) The Management has represented that, to the best of its knowledge and belief, other than as disclosed in the notes to the financial statements no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
    - (b) The Management has represented, that, to the best of its knowledge and belief, other than as disclosed in the notes to the financial statements, no funds have been received by the Company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

✓

**Deloitte  
Haskins & Sells LLP**

(c) Based on the audit procedures performed that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material misstatement.

- v. The company is not permitted to declare the dividends being the section 8 company.
- vi. Based on our examination, which included test checks, the Company has used an accounting software for maintaining its books of account for the financial year ended 31<sup>st</sup> March 2024 which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software(s).

Further, during the course of our audit, we did not come across any instance of the audit trail feature being tampered with.

As proviso to Rule 3(1) of the Companies (Accounts) Rules, 2014 is applicable from 1<sup>st</sup> April 2023, reporting under Rule 11 (g) of the Companies (Audit and Auditors) Rules, 2014 on preservation of audit trail as per the statutory requirements for record retention is not applicable for the financial year ended 31<sup>st</sup> March 2024.

- 2. As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government in terms of Section 143(11) of the Act, since the Order is not applicable to the company, being a company licensed to operate under section 8 of the companies Act, as specified in paragraph 1(2)(iii) of the Order.

For Deloitte Haskins & Sells LLP

Chartered Accountants

(Firm's Registration No. 117366W/W-100018)



**Jayesh Parmar**

(Partner)

(Membership No. 106388)

(UDIN : 24106388BKCUBB4067)

Place: Mumbai

Date: September 30, 2024

Assam Cancer Care Foundation  
Company limited by guarantee and not having share capital  
Balance Sheet as at March 31, 2024

Amount (Rs. in Lakhs)

Particulars	Note	As at March 31, 2024	As at March 31, 2023
<b>I EQUITY AND LIABILITIES</b>			
<b>1 Shareholders' funds</b>			
a) Share Capital	3	-	-
b) Reserves and Surplus	4	171.20	99.06
<b>2 Liabilities</b>			
<b>Non-Current Liabilities</b>			
a) Other Long Term Liabilities	5	1,88,167.76	1,54,679.26
b) Long Term Provisions	6	109.22	94.22
<b>Current Liabilities</b>			
a) <b>Trade Payables</b>	7		
ai) Total Outstanding dues to Micro Enterprises and Small Enterprises		181.94	66.81
aii) Total Outstanding dues of Creditors Other than Micro Enterprises and Small Enterprises		2,373.57	658.67
b) Earmarked funds	8	(4,042.62)	11,003.35
c) Other Liabilities	9	1,182.04	579.61
d) Short Term Provisions	10	19.36	27.64
<b>Total</b>		<b>1,88,162.47</b>	<b>1,67,208.62</b>
<b>II ASSETS</b>			
<b>1 Non-Current Assets</b>			
a) <b>Property, Plant and Equipment and Intangible assets</b>	11		
i) Property, Plant and Equipment	11A	1,08,382.25	1,01,376.71
ii) Intangible Assets	11B	43.92	75.74
iii) Assets Under Construction	11C	57,021.18	42,965.37
b) Long Term Loans and Advances	12	850.78	298.15
c) Other Non-Current Assets	13	6,778.23	6,171.02
<b>2 Current Assets</b>			
a) Trade Receivable	14	2,014.82	285.24
b) Cash and Bank Balances	15	12,824.60	15,651.78
c) Other Current Assets	16	246.69	384.61
<b>Total</b>		<b>1,88,162.47</b>	<b>1,67,208.62</b>

Notes to and forming part of the financial statements

1 - 47

In terms of our report attached  
**For Deloitte Haskins & Sells LLP**  
Chartered Accountants  
FRN: 117366W/W-100018



**Jayesh Parmar**  
Partner  
Membership No: 106388

For and on behalf of Board of Directors  
**Assam Cancer Care Foundation**  
CIN:- U74999AS2017NPL018256

  
**Siddharth Singh**  
Director  
DIN: 08251430

  
**Pattatheyil Arun**  
Director  
DIN: 10043845

Date: September 30, 2024  
Place: Mumbai

Date: September 30, 2024  
Place: Guwahati



Assam Cancer Care Foundation  
Company limited by guarantee and not having share capital  
Statement of Income and Expenditure for the year ended on March 31, 2024

Amount (Rs. in Lakhs)

Particulars	Note	Year Ended on March 31, 2024	Year Ended on March 31, 2023
<b>1 Income</b>			
a) Grant income	17	15,364.82	16,307.40
b) Other income	18	72.14	58.24
c) Income from treatment of patient charitable object		8,802.86	4,025.02
<b>Total Income</b>		<b>24,239.82</b>	<b>20,390.66</b>
<b>2 Expenditure</b>			
a) Employee Benefit Expenses	19	678.29	790.10
b) Project Expenses	20	281.32	151.36
c) Expenditure towards charitable objects	21	10,632.79	7,086.56
d) Depreciation and Amortizations	11	12,299.97	11,853.49
e) Establishment Expenses	22	275.31	450.92
<b>Total Expenditure</b>		<b>24,167.68</b>	<b>20,332.43</b>
<b>3 Excess of Income Over Expenditure</b>		<b>72.14</b>	<b>58.23</b>

Notes to and forming part of the financial statements

1 - 47

In terms of our report attached

**For Deloitte Haskins & Sells LLP**  
Chartered Accountants  
FRN: 117366W/W-100018



**Jayesh Parmar**  
Partner  
Membership No: 106388

**For and on behalf of Board of Directors**  
Assam Cancer Care Foundation  
CIN:- U74999AS2017NPL018256



**Siddharth Singh**  
Director  
DIN: 08251430



**Pattatheyil Arun**  
Director  
DIN: 10043845



Date: September 30, 2024  
Place: Mumbai

Date: September 30, 2024  
Place: Guwahati

**Assam Cancer Care Foundation**  
Company limited by guarantee and not having share capital  
Cash Flow Statement for the year ended on March 31,2024

Amount (Rs. in Lakhs)

Particulars	Year Ended on March 31, 2024	Year Ended on March 31, 2023
<b>A Cash flow from operating activities</b>		
Excess of Income over Expenditure	72.14	58.23
<b>Adjustments for non-cash items</b>		
Depreciation and amortization	12,299.97	11,853.49
Surplus on disposal of assets	-	(0.04)
Donated asset reserve release	(3,876.14)	(3,444.15)
Asset written off during the year	-	4.35
Foreign exchange gain/(loss)	-	19.02
<b>Operating Cash Flow Before Working Capital Adjustments</b>	<b>8,495.97</b>	<b>8,490.90</b>
<b>Adjustments for working capital:-</b>		
(Increase) in Long Term Loans and Advances	(552.63)	(239.58)
(Increase) in Trade receivable	(1,729.58)	(164.21)
(Increase)/Decrease in Other Assets	126.63	(112.37)
Increase in Liabilities and Provisions	(8,636.95)	(11,282.08)
<b>Net Cash Flow Generated From Operating Activities (A)</b>	<b>(2,296.56)</b>	<b>(3,307.34)</b>
<b>B Cash Flow From Investing Activity</b>		
Proceeds on sale of Property,Plant and Equipment	-	0.04
Bank deposits having maturity more than 3 months placed	(1,320.00)	(3,100.00)
Decrease in earmarked deposit with banks	-	565.66
Purchase of fixed assets and assets under constructions	(22,274.21)	(21,064.82)
<b>Net Cash (Used) from Investing Activities (B)</b>	<b>(23,594.21)</b>	<b>(23,599.12)</b>
<b>C Cash Flow From Financing Activity</b>		
Grant for Capital Assets/Under Construction *	18,597.98	20,336.32
<b>Net Cash Flow from Financing Activities (C)</b>	<b>18,597.98</b>	<b>20,336.32</b>
<b>D Net (Decrease) / Increase in Cash and Cash Equivalent (A+B+C)</b>	<b>(7,292.79)</b>	<b>(6,570.14)</b>
<b>E Cash and Cash Equivalent at Beginning of the Year</b>	<b>15,644.78</b>	<b>22,214.92</b>
<b>F Cash and Cash Equivalent at Closing of the Year</b>	<b>8,351.99</b>	<b>15,644.78</b>
<b>G Net (Decrease)/Increase in Cash and Cash Equivalent</b>	<b>(7,292.79)</b>	<b>(6,570.14)</b>

The Cash Flow Statement has been prepared in accordance with "Indirect Method" as set out in the Accounting Standard (AS) 3 on "Cash Flow Statements" as prescribed under section 133 of the Companies Act, 2013.

\* Donor funds received for acquisition of fixed assets and asset under construction

In terms of our report attached

**For Deloitte Haskins & Sells LLP**

**Chartered Accountants**

FRN: 117366W/W-100018



**Jayesh Parmar**

Partner

Membership No: 106388

**For and on behalf of Board of Directors**

**Assam Cancer Care Foundation**

CIN:- U74999AS2017NPL018256



**Siddharth Singh**

Director

DIN: 08251430



**Pattatheyil Arun**

Director

DIN: 10043845

Date: September 30,2024

Place: Mumbai

Date: September 30,2024

Place: Guwahati



**ASSAM CANCER CARE FOUNDATION**

**(Company limited by guarantee and not having share capital)**

**NOTES FORMING PART OF THE FINANCIAL STATEMENTS**

**1. Corporate Information:**

The Company has been established to conduct various projects and programs in connection with or relating to preventive care and medical treatment of Cancer. The Company was incorporated on December 5, 2017, limited by guarantee, and not having share capital pursuant to a license under Section 8(1) of the Companies Act, 2013 granted by the Ministry of Corporate Affairs, Government of India. The CIN of the Company is U74999AS2017NPL018256. The Company has received approval under Section 12A of the Income Tax Act, 1961 valid until March 31, 2026. The Company has also obtained registration under Section 80G of the Income Tax Act, 1961 valid until March 31, 2026.

The Company would incur expenditure directly towards objects and Programs which represent initiatives/activities undertaken by the Company.

**2. Material Accounting Policies:**

**A. Basis of Preparation of Financial Statements:**

The financial statements of the Company have been prepared and presented in accordance with the generally accepted accounting principles in India (Indian GAAP) to comply with the Accounting Standards specified under Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014, to the extent applicable.

The financial statements are prepared under the historical cost convention on accrual basis. The Company is a small and medium sized company as defined in the General Instructions in respect of Accounting Standards specified under section 133 of the Companies Act, 2013. Accordingly, the Company has complied with the Accounting Standards as applicable to a Small and Medium sized Company.

**B. Use of Estimates:**

The preparation of the financial statements in conformity with Indian GAAP requires the Management to make estimates and assumptions considered in the reported amounts of assets and liabilities (including contingent liabilities) and the reported income and expenses during the period. The Management believes that the estimates used in preparation of the financial statements are prudent and reasonable. Future results could differ due to these estimates and the differences between the actual results and the estimates are recognized in the periods in which the results are known / materialize.

**C. Revenue Recognition:**

- a) Earmarked grants are initially credited to a liability account in the Balance Sheet and are transferred to Statement of Income and Expenditure in the year in which and to the extent to which the Company complies with the conditions attached to them.
- b) Donations are recognized as income in Statement of Income and Expenditure in the period in which the collections are received to the extent of expenditure incurred
- c) The Company recognizes revenue from medical and healthcare services to patients, on sale of medical consumables and drugs within the hospital premises and on providing services towards patient amenities. Revenue is measured at the fair value of the consideration received or receivable. Revenue is recognized upon transfer of control of promised products or services to customers/ patients in an amount that reflects the consideration we expect to receive in exchange for those products or services. Sales and Service Income exclude Goods and Service Tax (GST) and are net of trade / volume discounts, where applicable. 'Unbilled



**ASSAM CANCER CARE FOUNDATION**

**(Company limited by guarantee and not having share capital)**

**NOTES FORMING PART OF THE FINANCIAL STATEMENTS**

revenue' represents value to the extent of medical and healthcare services rendered to the patients who are undergoing treatment/ observation on the balance sheet date and is not billed as at the balance sheet date.

- d) For patients falling under the category of government schemes, bills are raised and settled by the respective authorities based on the approved amounts. The actual value of treatment may however be lower than the approved amount. Excess of such receipts are treated as revenue in the year in which amounts are received. Deficit against bills/claims raised are charged to revenue in the year of settlement.
- e) Interest Income is recognized on time proportion basis considering the amount outstanding.

**D. Donations Received:**

Donations are accounted for when actually received. On receipt of donation the same is not taken as income but are transferred to Earmarked fund, and on utilization it gets transferred to either Capital Assets related fund or Income and Expenditure considering the nature of utilization.

**E. Fixed Assets:**

Tangible assets are stated at acquisition cost, net of accumulated depreciation and accumulated impairment losses, if any. Cost includes purchase price, taxes, and any attributable cost of bringing the assets to its working condition for its intended use.

Components of Grants utilized for meeting costs of capital assets are disclosed as ' Grant for Capital Assets ' as a part of 'Other Non-Current Liabilities'. Costs of such assets are capitalized. Amount equivalent to depreciation provided on such asset is released from Grant for Capital Assets to Income and Expenditure Account.

Donated assets have been recognized in the books at cost of acquisition of the donor, by creating an equivalent amount of reserve. Amount equal to depreciation on such donated assets is released from the reserve to Income and Expenditure Account.

**F. Depreciation/Amortization:**

Depreciable amount for assets is the cost of an asset, or other amount substituted for cost, less its estimated residual value. Depreciation would be calculated on Written Down Value method, except Intangible assets, which will be on Straight Line method. Depreciation would be provided as per the useful / estimated life prescribed in Schedule II to the Companies Act, 2013.

Individual assets/group of assets costing in aggregate less than Rs 10,000 are fully depreciated in the year of acquisition.

Categories of assets and their useful life based on Schedule II to the Companies Act 2013 is below:

Assets	Estimated Useful Life
Office Equipment	5 years
Computers and data processing units –	
a) Laptops and desktops	3 years
b) Other IT peripherals	6 years
Furniture and Fixtures	10 years
Building	60 years
Plant and Machinery	15 years



**ASSAM CANCER CARE FOUNDATION**

**(Company limited by guarantee and not having share capital)**

**NOTES FORMING PART OF THE FINANCIAL STATEMENTS**

Medical Equipment	
a) Electrical Machinery & other diagnostic equipment's	13 years
b) Other Equipment's	15 years
Lease hold Improvement	Over period of Lease
Motor Vehicles	8 years
Roads	10 years
Electrical Installations	10 years
Intangibles-Software	3 years

**G. Impairment of assets:**

In accordance with Accounting Standard 28 (AS 28) on "Impairment of assets", the carrying amounts of the Company's assets are reviewed at each balance sheet date to determine whether there is any impairment. Management periodically assesses using, external and internal sources, whether there is an indication that an asset may be impaired. An impairment occurs where the carrying value exceeds the present value of future cash flows expected to arise from the continuing use of the asset and its eventual disposal. The impairment loss to be expensed is determined as the excess of the carrying amount over the higher of the asset's net sales price or present value as determined above.

**H. Provision and Contingent Liabilities:**

Provisions are recognized when the Company has a present obligation because of a past event; it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and when a reliable estimate of the amount of the obligation can be made.

No Provision is recognized for –

Any possible obligation that arises from past events and the existence of which will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the Company; or

Any present obligation that arises from past events but is not recognized because-

- (i) It is not probable that an outflow of resources embodying economic benefits will be required to settle the obligation; or
- (ii) A reliable estimate of the amount of obligation cannot be made.

Such obligations are recorded as Contingent Liabilities. These are assessed periodically and only that part of the obligation for which an outflow of resources embodying economic benefits is probable, is provided for, except in the extremely rare circumstances where no reliable estimate can be made.

Contingent Assets are not recognized in the financial statements since this may result in the recognition of income that may never be realized.

**I. Expenses towards charitable objects of the trust:**

- a) All expenses are accounted for on accrual basis and provision is made for all known losses and liabilities.
- b) It includes expenditure incurred in operation and running of hospitals.

**J. Foreign Exchange Transactions:**

Transactions in foreign currency are recorded at the exchange rates prevailing on the date of the transaction. Exchange differences arising on settlement of revenue transactions are recognized in



**ASSAM CANCER CARE FOUNDATION**

**(Company limited by guarantee and not having share capital)**

**NOTES FORMING PART OF THE FINANCIAL STATEMENTS**

the Statement of Income and Expenditure. Monetary items denominated in a foreign currency are restated using the exchange rates prevailing at the date of the Balance Sheet and the resulting net exchange difference is recognized in the Statement of Income and Expenditure.

**K. Employee Benefits:**

**Short Term Employee Benefits**

All employee benefits payable wholly within twelve months of rendering the service are classified as short-term employee benefits. Benefits such as salaries, etc., are recognized as an expense at the undiscounted amount in the Statement of Income and Expenditure of the year in which the employee renders the related service.

**Post-employment Benefit Plans**

**Defined Contribution Plans:**

Payments made to a defined contribution plan such as Provident Fund are charged as an expense in the Statement of Income and Expenditure as they fall due. Contribution to Provident Fund is recognized as an expense in the income and expenditure account when the employees have rendered services entitling them to contributions.

**Defined Benefit Plans:**

The liability towards gratuity to past employees is determined using the Projected Unit Credit Method which considers each period of service as giving rise to an additional unit of benefit entitlement and measures each unit separately to build up the final obligation. Past services are recognized on a straight-line basis over the average period until the amended benefits become vested. Actuarial gain and losses are recognized immediately in the statement of Statement of Income and Expenditure as surplus or deficit. Obligation is measured at the present value of estimated future cash flows using a discounted rate that is determined by reference to market yields at the Balance Sheet date on Government Securities where the currency and terms of the Government Securities are consistent with the currency and estimate terms of the defined benefit obligations.

**Other Long Term Employee Benefits:**

Other Long Term Employee Benefits viz., leave encashment is recognized as an expense in the Statement of Income and Expenditure as and when it accrues. The liability is determined using the Projected Unit Credit Method, with the actuarial valuation carried out as at the Balance Sheet date. Actuarial gains and losses in respect of such benefits are charged to the Statement of Income and Expenditure.

**L. Income Tax:**

Income taxes have been computed using the tax effect accounting method, where taxes are accrued in the same period as the related revenue and expenses. Current tax is determined as the amount of tax payable in respect of taxable income for the year, as per provisions of the Income-tax Act, 1961.

**M. Cash and Cash Equivalents:**

Cash and Cash Equivalents includes cash in hand, bank balances and liquid term deposits with bank having maturity term of less than 90 days and deposits with bank having maturity term of more than 90 days are considered as other bank balances



**ASSAM CANCER CARE FOUNDATION**

**(Company limited by guarantee and not having share capital)**

**NOTES FORMING PART OF THE FINANCIAL STATEMENTS**

**N. Leases:**

Lease arrangements where the risks and rewards incidental to ownership of an asset substantially vest with the lessor are recognize as operating leases. Lease rentals under operating lease are recognised in the Statement of Income and Expenditure on a straight-line basis over the lease term.

**O. Operating cycle:**

Based on the nature of activities of the Company and the normal time elapsed between acquisition of assets and their realization in cash or cash equivalents, the Company has determined its operating cycle as 12 months for the purpose of classification of its assets and liabilities as current and non-current.

**P. General funds:**

The company generate general funds from various projects which are unrestricted in nature, which are carried forward for use in the future period. These funds are the excess of income over expenditure during the year.



**Assam Cancer Care Foundation**  
**Company limited by guarantee and not having share capital**  
**Notes to and forming part of Financial Statement**

**Note 3 Equity Share Capital**

The Company is a Private Limited Company within the meaning of Section 2 (68) of the Companies Act, 2013. The Company is limited by Guarantee and does not have a share capital. The liability of each member is restricted to Rs.1,000. If upon a winding up or dissolution of the Company, there remains, after the satisfaction of all the debts and liabilities, any sum of money or property whatsoever, the same shall not be distributed amongst the members of the Company but shall be given or transferred to such other company having objects similar to the objects of this Company, subject to such conditions as the Tribunal may impose, or may be sold and the proceeds thereof credited to the Insolvency and Bankruptcy Fund (IBF).

**Note 4 Reserves and Surplus**

Particulars	Amount (Rs. in Lakhs)	
	As at March 31, 2024	As at March 31, 2023
<u>Excess of Income over Expenditure</u>		
Balance at Beginning of the Year	99.06	40.83
Add: Excess of Income over Expenditure for current year	72.14	58.23
<b>Total</b>	<b>171.20</b>	<b>99.06</b>

**Note 5 Other Long Term Liabilities**

Particulars	Amount (Rs. in Lakhs)	
	As at March 31, 2024	As at March 31, 2023
<u>a. Grants for Capital Assets</u>		
Balance at Beginning of the Year	83,129.48	3,430.65
Add Transfer from Earmarked Funds (Refer Note 8)	170.02	224.67
Add Transfer from Grants for Capital Assets Under Construction (Refer Note 5-b)	18,037.69	87,883.50
Less Transfer to Statement of Income and Expenditure (Refer Note 17-b)	8,423.83	8,409.34
<b>Balance at Close of the Year</b>	<b>92,913.36</b>	<b>83,129.48</b>
<u>b. Grants for Capital Assets Under Construction</u>		
Balance at Beginning of the Year	46,022.07	1,11,990.58
Add Transfer from Earmarked Funds (Refer Note 8)	27,171.34	23,840.41
Transfer to/(from) Earmarked Funds (Mobilization Advance and Long Term Security Deposit) (Refer Note 13-d & 13-a)	(3,695.91)	1,925.42
Less Transfer to Grants for Capital Assets (Refer Note 11-c)	18,037.69	87,883.50
<b>Balance at Close of the Year</b>	<b>58,851.63</b>	<b>46,022.07</b>
<u>c. Reserve for Grant in Kind</u>		
Balance at Beginning of the Year	18,320.76	186.95
Add Received during the year (Refer Note 11-A-II & 11-C-2)	5,988.13	21,577.96
Less Depreciation transferred to revenue account (Refer Note 17-c)	3,876.14	3,444.15
<b>Balance at Close of the Year</b>	<b>20,432.75</b>	<b>18,320.76</b>
<u>d. Capital Creditors</u>	15,970.02	7,206.95
<b>Total</b>	<b>1,88,167.76</b>	<b>1,54,679.26</b>

**Note:** Reserve against "Grant in kind" represent the written down value of assets received as donation in kind, which have been accounted for at the cost of acquisition to the donor. It also includes donated assets amounting to Rs 4,922.16 Lakhs, which have not yet been capitalised as these have not yet been installed/put to use during FY 23-24.



Assam Cancer Care Foundation  
Company limited by guarantee and not having share capital  
Notes to and forming part of Financial Statement

**Note 6 Long Term Provisions**

Amount (Rs. in Lakhs)		
Particulars	As at March 31, 2024	As at March 31, 2023
<b>Provision for employee benefits:</b>		
a) Provision for Gratuity (Refer Note 27)	61.40	36.29
b) Provision for Leave Encashment (Refer Note 27)	47.82	57.93
<b>Total</b>	<b>109.22</b>	<b>94.22</b>

**Note 7 Trade Payables**

Amount (Rs. in Lakhs)		
Particulars	As at March 31, 2024	As at March 31, 2023
1 Total Outstanding dues of Micro Enterprises and Small Enterprises	181.94	66.81
2 Total Outstanding dues of Creditors Other than Micro Enterprises and Small Enterprises	2,373.57	658.67
<b>Total</b>	<b>2,555.51</b>	<b>725.48</b>

**a Trade Payable Ageing schedule**

Amount (Rs. in Lakhs)												
Particulars	Not due	Outstanding for following period from due date of payment as on March 31, 2024					Not due	Outstanding for following period from due date of payment as on March 31, 2023				
		Less than 1 year	1-2 years	2-3 years	More than 3 years	Total		Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
i. MSME	176.14	4.15	1.65	-	-	181.94	64.31	2.50	-	-	-	66.81
ii. Others	1,588.39	782.91	2.12	0.15	-	2,373.57	646.67	11.67	0.30	0.03	-	658.67
iii. Disputed dues-MSME	-	-	-	-	-	-	-	-	-	-	-	-
iv. Disputed dues-Others	-	-	-	-	-	-	-	-	-	-	-	-
<b>Total</b>	<b>1,764.53</b>	<b>787.06</b>	<b>3.77</b>	<b>0.15</b>	<b>-</b>	<b>2,555.51</b>	<b>710.97</b>	<b>14.17</b>	<b>0.30</b>	<b>0.03</b>	<b>-</b>	<b>725.48</b>

**b Disclosure required under section 22 of Micro, Small and Medium Enterprises Development Act, 2006 (the Act)**

Amount (Rs. in Lakhs)		
Particulars	As at March 31, 2024	As at March 31, 2023
Principal amount and interest due thereon remaining unpaid to any supplier at year end: -		
Principal	180.08	66.18
Interest due thereon	0.41	0.06
Amount of interest paid by the buyer in terms of section 16 of the Act, along with the amount of payment made to the supplier beyond the appointed date during each accounting year	-	-
Amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under the Act.	0.82	0.12
Amount of interest accrued and remaining unpaid at end of each accounting year	1.86	0.63
Amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues above are actually paid to the small enterprise, for the purpose of disallowance of a deductible expenditure under section 23 of the Act.	-	-

The amount due to Micro, Small and Medium Enterprise as defined in the "The Micro, Small and Medium Enterprises Development Act, 2006" has been determined to the extent such parties have been identified on the basis of the information collected by the Management.



**Assam Cancer Care Foundation**  
Company limited by guarantee and not having share capital  
Notes to and forming part of Financial Statement

**Note 8 Earmarked Funds**

Particulars	Amount (Rs. in Lakhs)	
	As at March 31, 2024	As at March 31, 2023
<u>Unspent Grant of Donor Agencies</u>		
Balance at Beginning of the Year (Including Interest)	11,003.35	16,354.89
Add Grants received during the year (Refer Note 24)	18,597.98	20,336.32
Add Interest earned during the year (Refer Note 24)	852.46	912.98
Less Transfer to Grants for Capital Assets (Refer Note 11)	170.02	224.67
Less Transfer to Grants for Capital Assets Under Construction (Gross) (Refer Note 11)	27,171.34	23,840.41
Add Transfer to/(from) Earmarked Funds (Mobilization Advance and Long Term Security Deposit) (Refer Note 13-d & 13-a)	(3,695.91)	1,925.42
Less Transfer from Earmarked Funds for Patient Support (Refer Note 24)	394.31	7.27
Less Transfer to Statement of Income and Expenditure (Refer Note 17-a)	3,064.85	4,453.91
	(4,042.62)	11,003.35

Note: The balance of Earmarked Funds represent -

- amount received from various donors and sponsors for specific projects under taken/ to be undertaken by the company which have remained unutilized/overutilised as at the Balance Sheet date, and
- interest accrued on the unspent balance from time to time.
- There is a negative balance at 31st March 2024 due to creation of provisions for project related work completed till year end, for which funds from donors have been received subsequent to the year end.

**Note 9 Other Liabilities**

Particulars	Amount (Rs. in Lakhs)	
	As at March 31, 2024	As at March 31, 2023
a) Statutory dues	269.49	153.40
b) Retention money	727.79	256.42
c) Employee benefit payable	81.33	51.15
d) Security deposit	71.69	82.15
e) Advance from customers	31.74	36.49
<b>Total</b>	<b>1,182.04</b>	<b>579.61</b>

**Note 10 Short Term Provisions**

Particulars	Amount (Rs. in Lakhs)	
	As at March 31, 2024	As at March 31, 2023
<u>Provision for employee benefits:</u>		
a) Provision for Gratuity (Refer Note 27)	8.50	4.84
b) Provision for Leave Encashment (Refer Note 27)	10.86	22.80
<b>Total</b>	<b>19.36</b>	<b>27.64</b>

**Note 12 Long Term Loans and Advances**

Particulars	Amount (Rs. in Lakhs)	
	As at March 31, 2024	As at March 31, 2023
Unsecured, considered good. To parties other than related parties		
a) Advance Income Tax (Including TDS & TCS)	850.78	298.15
<b>Total</b>	<b>850.78</b>	<b>298.15</b>

**Note 13 Other Non-Current Assets**

Particulars	Amount (Rs. in Lakhs)	
	As at March 31, 2024	As at March 31, 2023
Unsecured, considered good.		
a) Long term Security Deposit-APDCL	238.05	180.87
b) Long term Security Deposit-Others	12.32	14.32
c) Prepaid Expense	13.29	-
d) Mobilization Advance	6,514.57	2,875.83
e) Bank deposits (original maturity of more than 12 months)	-	3,100.00
<b>Total</b>	<b>6,778.23</b>	<b>6,171.02</b>



Note 11 Property, Plant, and Equipment and Intangible Assets

Sr. No.	Particulars	Gross Block (at Cost)					Depreciation			Net Block		
		As at April 1, 2023	Adjustment	Addition during the year	Deduction / Transfer/Sale during the year	Asset Written off	As at March 31, 2024	As at April 1, 2023	For the year	Adjustments during the year	As at March 31, 2024	As at March 31, 2023
A. Property, Plant and Equipment												
I) Tangible Assets purchased from Donors Funds												
1	Leasehold Land ( Refer Note - 11 b)	0.05	-	-	-	-	0.05	-	-	-	-	0.05
2	Building	61,362.79	(3.75)	13,218.08	-	-	74,577.12	2,604.15	2,919.34	0.35	5,523.14	58,758.64
3	Medical Equipments	5,316.60	-	112.72	-	-	5,429.32	1,485.19	805.33	-	2,290.52	3,831.41
4	Furniture and Fixtures	1,129.35	-	260.07	-	-	1,389.42	267.82	234.39	-	502.21	861.53
5	Laptops & Computers*	109.50	-	10.39	-	-	119.89	96.70	10.28	-	106.98	12.80
6	Office Equipments	187.68	(1.68)	35.70	-	-	221.70	67.98	55.80	(1.46)	122.32	119.70
7	Vehicle	11.69	-	-	-	-	11.69	9.02	0.83	-	9.85	2.67
8	Plant & Machinery	11,589.76	(69.14)	2,406.72	-	-	13,927.34	1,785.64	1,823.72	(24.10)	3,585.26	9,804.12
9	Leasehold Improvements	120.09	-	3.19	-	-	123.28	90.72	13.24	-	103.96	19.32
10	Roads	2,024.77	-	272.73	-	-	2,297.50	454.38	412.55	-	866.93	1,430.57
11	Electrical Installation & Equipment	10,436.73	-	1,951.12	-	-	12,387.85	2,371.46	2,130.88	-	4,502.34	7,885.51
	Total A (I)	92,289.01	(74.57)	18,270.72	-	-	1,10,485.16	9,233.06	8,406.36	(25.91)	17,613.51	83,055.95
	Previous Year	4,234.84	-	88,059.37	-	5.20	92,289.01	854.87	8,379.03	(0.84)	9,233.06	3,379.97
II) Tangible Assets received as donation in kind from Donors												
1	Vehicles	243.14	-	1.54	-	-	244.68	82.81	51.00	-	133.81	160.33
2	Medical Equipment	20,746.59	-	884.27	-	-	21,630.86	3,041.57	3,630.50	-	6,672.07	17,705.02
3	Medical Furniture	302.36	-	70.63	-	-	372.99	72.49	61.06	-	133.55	229.87
4	IT assets	489.18	-	109.53	-	-	598.71	263.63	133.58	-	397.21	225.55
	Total - A (II)	21,781.27	-	1,065.97	-	-	22,847.24	3,460.50	3,876.14	-	7,336.64	18,320.77
	Previous Year	203.30	-	21,577.96	-	-	21,781.26	16.35	3,444.15	-	3,460.50	186.95
	Total Tangible Assets - A [(I)] + A[(II)]	1,14,070.28	(74.57)	19,336.69	-	-	1,33,332.40	12,693.56	12,282.50	(25.91)	24,950.15	1,01,376.71
	Total Tangible Assets	4,438.14	-	1,09,637.33	-	5.20	1,14,070.27	871.22	11,823.18	0.84	12,693.56	3,566.92
B Intangible Assets												
	Software license	111.83	-	11.56	-	-	123.39	36.09	43.38	-	79.47	75.74
	Total Intangible Assets - B	111.83	-	11.56	-	-	123.39	36.09	43.38	-	79.47	75.74
	Previous Year	57.82	-	54.01	-	-	111.83	5.78	30.31	-	36.09	52.04



## Note 11 Property, Plant and Equipment and Intangible Assets Continued

C Capital Work in progress												
1	Capital Work in Progress - Own assets	42,965.37	40.13	27,131.21	18,037.69	-	52,099.02	-	-	-	52,099.02	42,965.37
2	Capital Work in Progress - Donated assets	-	-	4,922.16	-	-	4,922.16	-	-	-	4,922.16	-
	<b>Total Capital work in progress- C</b>	<b>42,965.37</b>	<b>40.13</b>	<b>32,053.37</b>	<b>18,037.69</b>	<b>-</b>	<b>57,021.18</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>57,021.18</b>	<b>42,965.37</b>
	<i>Previous Year</i>	<i>1,07,008.46</i>	<i>-</i>	<i>23,840.41</i>	<i>87,883.50</i>	<i>-</i>	<i>42,965.37</i>	<i>-</i>	<i>-</i>	<i>-</i>	<i>42,965.37</i>	<i>1,07,008.46</i>

## Amount (Rs. in Lakhs)

Particulars	Amount in CWIP for a period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects in progress (31-Mar-24)	14,055.81	12,259.71	14,187.86	16,517.79	57,021.18
Projects in progress (31-Mar-23)	12,259.72	14,187.86	13,429.72	3,088.07	42,965.37
Projects temporarily suspended	-	-	-	-	-

**b.** The Company has received land allotment letters from various authorities in the State of Assam as stated below

Site Name	Authority	Total Cost	Lease Period	Renewable (Y/N)
Barpeta	Deputy Commissioner, Barpeta	FOC	30 Years	Yes
Dibrugarh	Deputy Commissioner, Dibrugarh	FOC	30 Years	Yes
Tezpur	Deputy Commissioner, Tezpur	FOC	30 Years	Yes
Jorhat	Deputy Commissioner, Jorhat	FOC	30 Years	Yes
Lakhimpur	Deputy Commissioner, Lakhimpur	FOC	30 Years	Yes
Kokrajhar	Jt Sec., Bodoland Territorial Council	FOC	30 Years	Yes
Darrang	Deputy Commissioner, Darrang	FOC	30 Years	Yes
Silchar	Deputy Commissioner, Silchar	FOC	30 Years	Yes
Diphu	Jt Sec, Karbi Anglong Autonomous Council	Rs 4,775/-	-	N/A
Tinsukia	Deputy Commissioner, Tinsukia	FOC	30 Years	Yes
Golaghat	Deputy Commissioner, Golaghat	FOC	30 Years	Yes
Sivasagar	District Commissioner, Sivasagar	FOC	30 Years	Yes
Nalbari	Deputy Commissioner, Nalbari	FOC	30 Years	Yes
Dhubri	Deputy Commissioner, Dhubri	FOC	30 Years	Yes
Nagaon	Sadar Revenue Circle, Nagaon	FOC	Yet to be finalised	Yet to be finalised
Goalpara	Dudhnoi Revenue Circle, Goalpara	FOC	Yet to be finalised	Yet to be finalised

**c** Particulars of projects whose completion is overdue

Particulars-Projects in progress	To be completed in less than 1 year	Amount (Rs. in Lakhs)
Barpeta		700.94
Dibrugarh		2.96
Diphu		10,916.30
State Cancer Institute, Guwahati		31,135.10
Silchar		3,664.30
<b>Total</b>		<b>46,419.60</b>

**d** Donated assets have been valued at its original cost of acquisition to the donor and depreciated over its useful life as per the policy of the company.



Assam Cancer Care Foundation  
Company limited by guarantee and not having share capital  
Notes to and forming part of Financial Statement

**Note 14 Trade Receivable**

		Amount (Rs. in Lakhs)	
Particulars		As at March 31, 2024	As at March 31, 2023
1 Unsecured considered good		2,014.82	285.24
<b>Total</b>		<b>2,014.82</b>	<b>285.24</b>

**Trade Receivable Ageing Schedule**

		Amount (Rs. in Lakhs)											
Particulars	Outstanding for following period from due date of payment as on March 31, 2024						Outstanding for following period from due date of payment as on March 31, 2023						
	Less than 6 months	6 months 1 year	1-2 years	2-3 years	More than 3 years	Total	Less than 6 months	6 months 1 year	1-2 years	2-3 years	More than 3 years	Total	
i. Undisputed trade receivable - considered good	1,844.52	160.61	9.69	-	-	2,014.82	281.24	4.00	-	-	-	285.24	
ii. Undisputed trade receivable - which have significant increase in credit risk	-	-	-	-	-	-	-	-	-	-	-	-	
iii. Undisputed trade receivable - credit impaired	-	-	-	-	-	-	-	-	-	-	-	-	
iv. Disputed trade receivable - considered good	-	-	-	-	-	-	-	-	-	-	-	-	
v. Disputed trade receivable - which have significant increase in credit risk	-	-	-	-	-	-	-	-	-	-	-	-	
v. Disputed trade receivable - credit impaired	-	-	-	-	-	-	-	-	-	-	-	-	
<b>Total</b>	<b>1,844.52</b>	<b>160.61</b>	<b>9.69</b>	<b>-</b>	<b>-</b>	<b>2,014.82</b>	<b>281.24</b>	<b>4.00</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>285.24</b>	

**Note 15 Cash and Bank Balances**

		Amount (Rs. in Lakhs)	
Particulars		As at March 31, 2024	As at March 31, 2023
<b>A) Cash and Cash Equivalents</b>			
i) Balance with scheduled banks			
In Current Account	9.93	5.97	
In Savings Account	6,000.41	7,261.58	
In Corporate Liquid Term Deposit	2,332.00	8,371.85	
ii) Cash on hand	9.65	5.38	
	<b>8,351.99</b>	<b>15,644.78</b>	
<b>B) Other Bank balances</b>			
i) Earmarked Deposits on lien*	7.00	7.00	
ii) In Fixed Deposit Account (maturity more than 3 months)	4,465.61	-	
	<b>4,472.61</b>	<b>7.00</b>	
	<b>12,824.60</b>	<b>15,651.78</b>	

\*The earmarked deposits on lien represents performance guarantee placed with our customers.

**Note 16 Other Current Assets**

		Amount (Rs. in Lakhs)	
Particulars		As at March 31, 2024	As at March 31, 2023
Unsecured considered good.			
a) Interest Accrued	24.58	288.99	
b) Prepaid Expenses	172.48	80.08	
c) Security Deposits	7.25	4.42	
d) Advance to creditors	42.38	11.12	
<b>Total</b>	<b>246.69</b>	<b>384.61</b>	



Assam Cancer Care Foundation  
Company limited by guarantee and not having share capital  
Notes to and forming part of Financial Statement

**Note 17 Grant Income**

Amount (Rs. in Lakhs)

Particulars	Year Ended on March 31, 2024	Year Ended on March 31, 2023
a) Transferred from Earmarked Funds (Refer Note 24)	3,064.85	4,453.91
b) Transferred from Capital Grant Funds (Refer Note 5-a)	8,423.83	8,409.34
c) Transfer from Reserve for Grant in kind (Refer Note 5-c)	3,876.14	3,444.15
<b>Total</b>	<b>15,364.82</b>	<b>16,307.40</b>

**Note 18 Other Income**

Amount (Rs. in Lakhs)

Particulars	Year Ended on March 31, 2024	Year Ended on March 31, 2023
a) Bid document/Processing fees	-	0.05
b) Interest on IT refund	2.39	3.97
c) Surplus on disposal of assets	-	0.04
d) Other Income	32.56	26.71
e) Interest received	37.19	27.47
<b>Total</b>	<b>72.14</b>	<b>58.24</b>

**Note 19 Employee Benefit Expenses**

Amount (Rs. in Lakhs)

Particulars	Year Ended on March 31, 2024	Year Ended on March 31, 2023
a) Salaries and Wages	550.42	614.88
b) Contribution to Provident Fund & Employees State Insurance	25.29	29.30
c) Contribution to Gratuity	29.31	19.72
d) Staff Welfare and Training	23.26	25.07
e) Stipend paid	-	0.15
f) Recruitment expenses	50.01	100.98
<b>Total</b>	<b>678.29</b>	<b>790.10</b>

**Note 20 Project Expenses**

Amount (Rs. in Lakhs)

Particulars	Year Ended on March 31, 2024	Year Ended on March 31, 2023
a) Travel and Conveyance	42.34	40.20
b) Power and Fuel Charges	37.64	0.56
c) Rental Charges	9.32	6.05
d) Repairs and Maintenance	0.70	1.79
e) Inauguration Expenses	59.82	86.79
f) Guest House expenses	0.98	0.36
g) Printing & Stationery	1.90	0.09
h) Security guard charges	16.68	10.27
i) Professional fees	97.20	-
j) Housekeeping Expenses	7.01	-
k) Contractual Manpower Expenses	7.73	5.25
<b>Total</b>	<b>281.32</b>	<b>151.36</b>



Assam Cancer Care Foundation  
Company limited by guarantee and not having share capital  
Notes to and forming part of Financial Statement

**Note 21 Expenditure towards Charitable Objects**

Particulars	Amount (Rs. in Lakhs)	
	Year Ended on March 31, 2024	Year Ended on March 31, 2023
a) <u>Hospital Operating Expenses</u>		
a.i) Awareness, Screening and Events	41.45	4.11
a.ii) Cost of Medicine Purchase	1,896.01	852.82
a.iii) Patient accomodation expense	25.94	21.51
a.iv) Medical & Surgical Consumables	252.37	181.65
a.v) Office Expenses	128.39	88.95
a.vi) Hostel expense	-	204.24
a.vii) Housekeeping Expenses	441.01	291.77
a.viii) Power and Fuel charges	1,404.10	1,033.38
a.ix) Contribution to Provident Fund & Employees State Insurance	89.53	74.75
a.x) Salaries and Wages	1,872.73	1,672.61
a.xi) Professional fees	1,683.41	1,077.71
a.xii) Other Operating Expenses	150.24	77.62
a.xiii) Registration and Licensing	92.07	20.33
a.xiv) Repairs and Maintenance	0.85	0.68
a.xv) Staff Welfare and Training	58.19	62.58
a.xvi) Image archiving and storage expense	33.87	-
a.xvii) Contractual Manpower Expenses	331.77	261.89
b) <u>Hospital Operating Expenses - State Cancer Institute</u>		
b.i) Housekeeping Expenses	99.94	95.90
b.ii) Office Expenses	1.05	2.98
b.iii) Repairs and Maintenance	45.34	1.31
b.iv) Power and Fuel charges	13.73	1.75
b.v) Contractual Manpower Expenses	76.01	69.79
c) <u>Others</u>		
c.i) Telephone & Internet Expenses	41.97	31.16
c.ii) Travel and Conveyance	179.17	143.64
c.iii) Printing & Stationery	56.75	41.68
c.iv) Advertisement	16.79	4.11
c.v) Staff Welfare and Training	28.97	15.81
c.vi) Repairs and Maintenance	358.00	42.14
c.vii) Contractual Manpower Expenses	453.32	333.96
c.viii) Office Expenses	82.34	43.48
c.ix) Rental charges	14.21	13.95
c.x) Security guard charges	381.96	309.74
c.xi) Cloud Service Expenses	131.27	4.46
c.xii) Guest House expenses	3.01	1.87
c.xiii) Information Technology expenses	3.03	2.23
c.xiv) Insurance other assets	73.01	-
c.xv) Professional fees	70.99	-
	<b>10,632.79</b>	<b>7,086.56</b>



Assam Cancer Care Foundation  
Company limited by guarantee and not having share capital  
Notes to and forming part of Financial Statement

**Note 22 Establishment Expenses**

Particulars	Amount (Rs. in Lakhs)	
	Year Ended on March 31, 2024	Year Ended on March 31, 2023
a) Advertisement expenses	0.56	5.97
b) Rental charges	69.37	60.38
c) Guest House expenses	1.81	2.35
d) Printing & Stationery	5.32	4.90
e) Auditors remuneration (Refer note below)	10.39	10.61
f) Information Technology expenses	5.77	24.14
g) Insurance other assets	-	10.18
h) Telephone & Internet expenses	8.23	18.14
i) Postage & Courier charges	5.00	3.02
j) Power and Fuel Charges	23.02	12.45
k) Office expenses	21.25	22.26
l) Cloud Service Expenses	8.63	5.64
m) Professional fees	45.03	186.73
n) Travel and Conveyance	44.32	37.75
o) Repairs and Maintenance	1.11	2.42
p) Foreign exchange loss/(Gain)	-	19.02
q) Security guard charges	3.56	0.42
r) Contractual Manpower Expenses	21.94	24.54
<b>Total</b>	<b>275.31</b>	<b>450.92</b>

**Note:- Auditor's remuneration (inclusive of GST)**

	Amount (Rs. in Lakhs)	
a) For Statutory Audit Fees	9.58	9.58
b) Out of Pocket Expenses	0.22	0.44
c) Certification matters	0.59	0.59
<b>Total</b>	<b>10.39</b>	<b>10.61</b>



Assam Cancer Care Foundation  
Company limited by guarantee and not having share capital  
Notes to and forming part of Financial Statement

**Note 23 Ratio Analysis**

Ratio	Numerator	Denominator	FY 2023-2024	FY 2022-2023	Variance	%	Reason for change (Refer Note below)
(a) Current ratio	Current Asset	Current Liabilities	-52.80	1.32	-54.12	-4091%	Refer below Note 1
(b) Debt-equity ratio			Not applicable				Refer below Note 2
(c) Debt service coverage ratio			Not applicable				Refer below Note 2
(d) Return on equity ratio			Not applicable				Refer below Note 3
(e) Inventory turnover ratio			Not applicable				Refer below Note 4
(f) Trade receivables turnover ratio			Not applicable				Refer below Note 5
(g) Trade payables turnover ratio			Not applicable				Refer below Note 5
(h) Net capital turnover ratio			Not applicable				Refer below Note 5
(i) Net profit ratio			Not applicable				Refer below Note 5
(j) Return on capital employed			Not applicable				Refer below Note 5
(k) Return on investment			Not applicable				Refer below Note 6

**Notes:**

- 1) The ratio for FY 23-24 is negative due to the negative balance of Current liabilities as at 31st March 24. It is due to creation of provisions for project related work completed till year end, for which funds from donors have being received subsequent to the year end.
- 2) The company does not have any debt taken during the year or outstanding of earlier year. Thus this ratio is not applicable
- 3) The entity is section 8 company with limited guarantee. There is no equity share capital authorized/issued. Thus this ratio is not applicable.
- 4) We are providing services and there is no inventory. Hence this ratio is not applicable.
- 5) The entity is section 8 company i.e. a not for profit organization. Thus there is no profit motive involved thus, this ratio is not applicable
- 6) The company does not have investment. Thus this ratio is not applicable



**Assam Cancer Care Foundation**  
Company limited by guarantee and not having share capital  
Notes to and forming part of Financial Statement

**Note 24 Unspent Grant of Donor Agencies**

Sr #	Name of the donor	Opening Principal Balance as on April 1, 2023	Opening Interest as on April 1, 2023	Received / (-) Refund during the year	Interest Earned during year	Total balance	Utilised-Purchase of Fixed Assets	Transfer to Income /Expenditure	Utilised for Patient support	Total Utilised	Closing Principal Balance as on March 31, 2024	Closing Interest Balance as on March 31, 2024
1	D Mart Foundation	37.36	0.57	172.55	2.58	213.06	-	114.82	95.09	209.91	-	3.15
2	Tata Education and Development Trust	-	8.43	-	0.91	9.34	-	-	-	-	-	9.34
3	Tata Education and Development Trust	-	3,043.29	-	329.45	3,372.74	-	-	-	-	-	3,372.74
4	Government of Assam*	3,135.16	4,644.32	18,000.00	514.24	26,293.72	30,883.83	2,887.17	-	33,771.00	(12,635.84)	5,158.56
5	Numaligarh Refineries Ltd	2.08	38.34	-	4.38	44.80	-	-	-	-	2.08	42.72
6	Tata Education and Development Trust (BPCL)	(0.88)	52.72	101.58	-	153.42	153.42	-	-	153.42	-	-
7	Indusind Bank Ltd (Grant MoU.001)	-	3.39	-	0.37	3.76	-	-	-	-	-	3.76
8	Tata Cancer Care Foundation (Pfizer)	37.98	0.34	-	0.53	38.85	-	37.98	-	37.98	-	0.87
9	Brahmaputra Cracker & Polymer Grant Ltd	-	-	22.40	-	22.40	-	22.40	-	22.40	-	-
10	Fedbank Hormis Memorable Foundation	-	-	300.00	-	300.00	-	0.78	299.22	300.00	-	-
11	Tata Education and Development Trust (EAP)	0.25	-	1.45	-	1.70	-	1.70	-	1.70	-	-
<b>Total</b>		<b>3,211.95</b>	<b>7,791.40</b>	<b>18,597.98</b>	<b>852.46</b>	<b>30,453.79</b>	<b>31,037.25</b>	<b>3,064.85</b>	<b>394.31</b>	<b>34,496.41</b>	<b>-12,633.76</b>	<b>8,591.14</b>
<i>Previous Year</i>		<i>9,476.49</i>	<i>6,878.42</i>	<i>20,336.32</i>	<i>912.98</i>	<i>37,604.19</i>	<i>22,139.68</i>	<i>4,453.91</i>	<i>7.27</i>	<i>26,600.86</i>	<i>3,211.95</i>	<i>7,791.40</i>

Note: The amount unutilized from Earmarked Funds represent -

i) Amount received from various donors and sponsors for specific projects under taken/ to be undertaken by the company which have remained unutilized/overutilised as at the Balance Sheet date.

ii) Interest accrued on the unspent balance from time to time.

iii) As per the requirement, Earmarked funds should be disclosed project wise, however since there is only one project carried out by the company the project wise movement could not be disclosed.

\*There is a negative balance at 31st March 2024 due to creation of provisions for project related work completed till year end, for which funds from donors have been received subsequent to the year end. (An amount of Rs 14,500 Lakhs received during April 24 till September 24)



**Assam Cancer Care Foundation**  
**Company Limited by Guarantee and not having share capital**  
**Notes to and forming part of Financial Statement**

**Note 25 Capital Commitments**

Estimated amount of contracts remaining to be executed on capital account, net of advance, and not provided for Rs. 51,521.35 Lakhs (Previous year Rs. 18,995.20 Lakhs)

**Note 26 Contingent Liabilities**

The Company has a contingent liability amounting to Rs. 5,679.70 Lakhs on account of escalation claims raised by L&T for the Extension of Time (EOT) for Phase I projects. (Previous year NIL)

**Note 27 Disclosure in respect of employee benefits under Accounting Standard (AS) - 15 (Revised) "Employee Benefits" prescribed under section Companies (Accounting Standards) Rules, 2006.**

**a) Defined Contribution Plan**

Both the employees and the Company make predetermined contribution to the Provident Fund and ESIC. Amounts recognised as expense towards employers' contribution to Provident Fund and ESIC amounted to Rs. 105.02 Lakhs (Previous Year Rs. 94.87 Lakhs) and Rs. 9.80 Lakhs (Previous Year Rs. 9.18 Lakhs) respectively and included in note 19 and 21 to the financial statement.

**b) Defined Benefit Plan**

Expense recognised on account of Gratuity is Rs. 29.31 Lakhs (Previous Year Rs. 19.72 Lakhs).

The following disclosures are made in compliance with the Accounting Standard 15 - "Employee Benefits" based on independent actuarial valuation

Particulars	Amount (Rs. in Lakhs)	
	For the year ended 31 March, 2024	For the year ended 31 March, 2023
<b>i) Change in Present Value of Defined Benefit Obligation</b>		
Present value of the obligation at the beginning of the year	41.13	82.35
Current Service Cost	14.40	18.55
Liability transferred in *	-	0.55
Benefit paid directly by the employer	(0.54)	-61.49
Actuarial (Gains)/Losses on Obligations - Due to change in Financial Assumptions	(7.52)	(0.36)
Actuarial (Gains)/Losses on Obligations - Due to change in Experience	8.82	10.97
Actuarial (Gains)/Losses on Obligations - Due to change in Demographic assumption	10.72	(15.01)
Interest Cost	2.89	5.57
Present value of the obligation at the end of the year	69.90	41.13
<b>ii) Amounts Recognised in the Balance Sheet:</b>		
Present value of Benefit Obligation at the end of the year	(69.90)	(41.13)
Fair value of Plan	-	-
Funded status (Surplus/(-)Deficit)	(69.90)	(41.13)
Net Obligation at the end of the year	(69.90)	(41.13)
<b>iii) Expense Recognised in the Statement of Profit and Loss:</b>		
Current Service Cost	14.40	18.55
Actuarial (Gains)/Losses on Obligations - Due to change in Financial Assumptions	(7.52)	(0.36)
Actuarial (Gains)/Losses on Obligations - Due to change in Experience	8.82	10.97
Actuarial (Gains)/Losses on Obligations - Due to change in Demographic assumption	10.72	(15.01)
Interest cost	2.89	5.57
Net Cost Included in Personnel Expenses	29.31	19.72



**Assam Cancer Care Foundation**  
**Company Limited by Guarantee and not having share capital**  
**Notes to and forming part of Financial Statement**

Particulars	For the year ended 31 March, 2024	For the year ended 31 March, 2023
<b>iv) Actuarial Assumptions</b>		
i) Discount Rate	7.17%	7.29%
ii) Salary Escalation rate	6.00%	8.20%
iii) Employee Turnover	17.00%	27.14%
iv) Mortality	Indian Assured Lives Mortality (2012-14) Urban	Indian Assured Lives Mortality (2012-14) Urban

The estimates of future salary increases, considered in actuarial valuation, take account of inflation, seniority, promotion and other relevant factors, such as supply and demand in the employment market.

\* This amount represent the gratuity in respect of employees who have been transferred to the Company.

**v) Experience Adjustments**

Amount (Rs. in Lakhs)

Experience Adjustments (Gain) / Loss:	For the year ended 31 March, 2024	For the year ended 31 March, 2023
On Plan Liabilities	8.82	10.97

**c.i) Defined benefit plan - Compensated absences - Unfunded**

Compensated absences as at balance sheet date, determined on the basis of actuarial valuation based on the 'Projected unit credit method' is Rs. 58.68 Lakhs (Previous Year Rs. 80.73 Lakhs) Refer Note 6-b and 10-b.

Expenses reversal recognised on account of Compensated absences is Rs. 14.70 Lakhs (Previous Year expenses recognised is Rs. 78.96 Lakhs).

**c. ii) Actuarial assumptions for long-term compensated absences - Unfunded**

Particulars	For the year ended 31 March, 2024	For the year ended 31 March, 2023
i) Discount Rate	7.17%	7.29%
ii) Salary Escalation Rate	6.00%	8.20%
iii) Rate of Employee Turnover	17.00%	27.14%

**Note 28 Details of Leasing arrangements**

As Lessee: -

i) The Company has entered into Operating Lease arrangements for certain facilities. The tenor of lease varies from eleven months to one hundred and eight months and may be renewed further based on mutually agreed terms. Further, none of the lease agreements carries any lock in period as on 31st March'2024.

ii) The total lease payments recognised in the Statement of Income and Expenditure for the year is Rs. 92.90 Lakhs (Previous Year Rs. 80.31 Lakhs).

**Note 29 Tax Status of the Company**

The Company is registered under Section 12AA of the Income Tax Act, 1961 which entitles it to claim an exemption from income tax, provided certain conditions laid down in the Income Tax Act, 1961 are complied with. Provision for income tax would be made only in the year in which the Company is unable to establish reasonable certainty of its ability to fulfil these conditions. The company has also taken a reregistration under section 12A as prescribed through the amendment of the Finance Act 2020. The Company has also obtained a new certificate under Section 80G of the Income Tax Act, 1961 as prescribed through the amendment of the Finance Act 2020. The registrations have been obtained for a period of five years commencing from assessment year 2022-23.



**Assam Cancer Care Foundation**  
**Company Limited by Guarantee and not having share capital**  
**Notes to and forming part of Financial Statement**

**Note 30 Undisclosed Income**

There are no transactions which has not been recorded in the books of account and which has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961.

**Note 31 Foreign Currency Transactions**

Value of imports on CIF basis in respect of Capital Goods - NIL (Previous year NIL)

**Note 32 Segment Reporting**

The company is registered as a section 8 company established to undertake various projects and programmes for treatment of cancer as primary and secondary segments. The same represents a single business segment, which operates in India and no separate segmentation or reporting is required as per the Accounting Standard 17 " Segment Reporting "

**Note 33 Relationship with Struck off Companies**

The company has not entered into any transactions with companies, other than those mentioned below, whose name is struck off under Section 248 of the Companies Act, 2013 or Section 560 of the Companies Act, 1956 during the year ended 31st March 2024.

Name of struck-off company	Nature of transaction	Balance outstanding-Rs Lakhs	Relationship
Reliant Engineers	Construction projects	-0.87	No relation

The company has not entered into any transactions with companies, other than those mentioned below, whose name is struck off under Section 248 of the Companies Act, 2013 or Section 560 of the Companies Act, 1956 during the year ended 31st March 2023.

Name of struck-off company	Nature of transaction	Balance outstanding-Rs Lakhs	Relationship
Valentia De Force Pvt Ltd	Security guard services	Nil	No relation

**Note 34 Details of Benami Property held**

No proceeding has been initiated or pending against the company for holding any benami property under the Benami Transactions (Prohibition) Act, 1985 (45 of 1988) and rules made thereunder.

**Note 35 Wilful Defaulter**

The company has not been declared as a wilful defaulter by any bank or financial institution or other lender.

**Note 36 Registration of charges or satisfaction with Registrar of Companies**

No charges for registration or satisfaction, beyond the statutory period, are pending to be registered with Registrar of Companies.

**Note 37 Loans and advances**

The company has not given any loans or advances in the nature of loans to promoters, directors, Key Management Personnel (KMP) and related parties as defined under the Companies Act, 2013.

**Note 38 Crypto Currency or Virtual Currency**


The Company has not traded or invested in Crypto Currency or Virtual Currency during the financial year.

**Note 39 Compliance with number of layers of companies**

There are no subsidiary companies as defined under section 2(87) of the Companies Act, 2013 and hence no disclosures are required to be made.

**Note 40 Corporate Social Responsibility (CSR)**

The company is not required to comply with the provisions of section 135 of the Companies Act, 2013 and hence no disclosure is made under CSR.



**Assam Cancer Care Foundation**  
**Company Limited by Guarantee and not having share capital**  
**Notes to and forming part of Financial Statement**

**Note 41 Utilization of funds**

There are no funds which have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person(s) or entity (ies), including foreign entities ("Intermediaries") with the understanding, whether recorded in writing or otherwise, that the Intermediary shall lend or invest in party identified by or on behalf of the company (Ultimate Beneficiaries). The company has not received any fund from any party(s) (Funding Party) with the understanding that the company shall whether directly or indirectly lend or invest in other person or entities identified by or on behalf of the company (Ultimate Beneficiaries) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

There are no funds which have been received by the company from any other person(s) or entity (ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall directly or indirectly, lend or invest in other person or entities identified in any manner whatsoever (Ultimate Beneficiaries") by or on behalf of the Funding Party or provide any guarantee, security or the like from or on behalf of the Ultimate Beneficiaries.

**Note 42 Compliance with approved Scheme(s) of Arrangements**

No Scheme(s) of Arrangements has been approved by the Competent Authority in terms of section 230 to 237 of the Companies Act, 2013.

**Note 43 Borrowings of funds**

The company has not borrowed funds from any banks or financial institutions on the basis of security of current assets.

**Note 44 Revaluation of Property, Plant and Equipments**

The company has not revalued any of its assets for the period ended 31st March 2024 and 31st March 2023.

**Note 45 Other Note**

Information with regards to other matters specified in Schedule III, Division I to Companies Act, 2013 is not applicable for the year ended March 31, 2024.

**Note 46 Subsequent Events after the reporting period**

There are no such events for the period ended 31st March 2024 and 31st March 2023.

**Note 47 Previous Year Figures**

- i) Previous year's figure of Rs 2,875.83 Lakhs is regrouped and reclassified from Short Term Loans and Advances to Other Non-Current Assets (Note 13) as per the Schedule III disclosure requirement.
- ii) Earmarked funds (Note 8) of Rs 11,003.35 Lakhs has been disclosed separately, whereas in the previous year it was forming part of Other Current Liabilities (Note 9)

**For and on behalf of Board of Directors**  
**Assam Cancer Care Foundation**

  
**Siddharth Singh**  
Director  
DIN: 08251430

  
**Pattatheyil Arun**  
Director  
DIN: 10043845



Date: September 30, 2024  
Place: Guwahati

